The Zhitong Finance App learned that Nuocheng Jianhua (09969) rose more than 5% in the intraday period. As of press release, it had risen 1.53% to HK$14.01, with a turnover of HK$153 million.

According to the news, Nuochengjianhua recently announced that ICP-B208, a novel ADC innovative drug targeting CDH17 developed independently by the company, has completed the first patient administration. Based on the ADC technology platform independently developed by Nuochengjianhua, ICP-208 is formed by coupling a humanized anti-CDH17 antibody with a potent payload independently developed by the company through protease lytic ligands, which can accurately target tumor cells while minimizing off-target effects.

Huaxi Securities released a research report stating that the company's self-research system is mature, sales of core listed products have maintained steady and rapid growth, and reserves of major products are abundant in the later stages; the integrated layout of domestic and foreign R&D companies is perfect, and overseas BD licensing results are remarkable. I am optimistic about the commercial expansion potential of the company after its newly approved products continue to be launched, and there is strong certainty about long-term growth. Using the free cash flow DCF discount valuation method, the company's valuation was 64.98 billion yuan, corresponding to a stock price of 36.73 yuan. It was covered for the first time, giving the company a “buy” rating.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.